Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tae Hata
Observed names:
Hata, Tae,
T. Hata,
TAE HATA
Institutions:
Kyoto Prefectural University of Medicine,
Rakuwakai Otowa Hospital
Observed institutions:
Kyoto Prefectural University of Medicine,
Rakuwakai Otowa Hospital
ORCID:
0000-0002-0598-2280
Observed ORCID:
0000-0002-0598-2280
OpenAlex ID:
A5043547580
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study
2024
·
Naoya Nishioka
, Tae Hata
, et al.
·
Cancer Research and Treatment
·
11
PDF
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
2025
·
Kenji Morimoto
, Tadaaki Yamada
, et al.
·
Lung Cancer
·
10
PDF
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan
2025
·
Shiho Goda
, Tadaaki Yamada
, et al.
·
Translational Lung Cancer Research
·
6
Wild-type Transthyretin Amyloidosis with Diffuse Alveolar-septal Amyloidosis Diagnosed by a Transbronchial Lung Biopsy
2022
·
Masaki Ishida
, Masamitsu Enomoto
, et al.
·
Internal Medicine
·
6
PDF
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
2025
·
Tae Hata
, Tadaaki Yamada
, et al.
·
Cancer Research Communications
·
5
PDF
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR‐TKI in non–small cell lung cancer patients with EGFR mutation: A multicenter retrospective study
2023
·
Tae Hata
, Chikara Sakaguchi
, et al.
·
Thoracic Cancer
·
5
PDF
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression
2025
·
Hayato Kawachi
, Tae Hata
, et al.
·
Translational Lung Cancer Research
·
2
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure
2025
·
Kenji Morimoto
, Tadaaki Yamada
, et al.
·
Targeted Oncology
·
2
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study
2022
·
Tae Hata
, Chikara Sakaguchi
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
2
Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database
2025
·
Masaki Ishida
, Tadaaki Yamada
, et al.
·
Lung Cancer
·
1
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study
2025
·
Kenji Morimoto
, Tadaaki Yamada
, et al.
·
International Journal of Clinical Oncology
·
1
Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression
2025
·
K. Morimoto
, T. Yamada
, et al.
·
ESMO Real World Data and Digital Oncology
·
1
PDF
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
2025
·
Tae Hata
, Tadaaki Yamada
, et al.
·
Lung Cancer
·
1
PDF
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non–Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study
2025
·
Tae Hata
, Tadaaki Yamada
, et al.
·
Clinical Lung Cancer
·
1
PDF
ERRATUM: Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study
2026
·
Naoya Nishioka
, Tae Hata
, et al.
·
Cancer Research and Treatment
PDF
Osimertinib vs. erlotinib combined with an angiogenesis inhibitor in EGFR-mutated non-small cell lung cancer with malignant pleural effusion: a retrospective cohort study
2026
·
Tae Hata
, Tadaaki Yamada
, et al.
·
Translational Lung Cancer Research
Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer
2026
·
Masaki Ishida
, Tadaaki Yamada
, et al.
·
iScience
Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR -mutant NSCLC After TKI Resistance
2026
·
HARUKA NAKATANI
, HAYATO KAWACHI
, et al.
·
Anticancer Research
Abstract 5238: Retrospective study for clinical biomarkers to guide post-EGFR-TKI treatment strategies in EGFR-mutant NSCLC
2026
·
Tadaaki Yamada
, Kenji Morimoto
, et al.
·
Cancer Research
1013P Impact of chemoimmunotherapy approval on post-EGFR-TKI treatment outcomes in EGFR-mutant NSCLC: Insights from a real-world Japanese cohort
2025
·
T. Yamada
, K. Morimoto
, et al.
·
Annals of Oncology
Figure 3 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
2025
·
Tae Hata
, Tadaaki Yamada
, et al.
Data from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
2025
·
Tae Hata
, Tadaaki Yamada
, et al.
Supplementary Table S1 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
2025
·
Tae Hata
, Tadaaki Yamada
, et al.
Supplementary Figure S2 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
2025
·
Tae Hata
, Tadaaki Yamada
, et al.
Supplementary Methods from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
2025
·
Tae Hata
, Tadaaki Yamada
, et al.
Show more works
View as search
Works count:
47
Citation count:
54
H-index:
5
I10-index:
2
Year
Topic
Type